FGP
RMD icon

Freestone Grove Partners’s ResMed RMD Stock Holding History

Freestone Grove Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
+7,826
New +$1.62M 0.01% 465

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Freestone Grove Partners's RMD Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in ResMed (RMD) in Q2 2026: 7,826 shares worth $1.53M. The stake represents 0.01% of the portfolio and ranks #465 among its holdings.

882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Freestone Grove Partners held 7,826 shares of ResMed worth $1.53M as of Q2 2026.
  • ResMed was a new Freestone Grove Partners position in Q2 2026.
  • ResMed made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #465 holding.
  • 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.